Home > Products > CD64 & EGFR
> Human Anti-CD64 x Anti-EGFR Bispecific Antibody (IgG-IgG)
Human Anti-CD64 x Anti-EGFR Bispecific Antibody (IgG-IgG) (CAT#: BSIG-H297)
Anti-CD64 x Anti-EGFR Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD64 and anti-EGFR parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can retarget neutrophils cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.
Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC)Renal cell cancer (RCC) Solid tumors
FCGR1A; Fc fragment of IgG receptor Ia; CD64; FCRI; CD64A; IGFR1; Cluster of Differentiation 64; FcγRI; FCGR1B; FCGR1C; immunoglobulin G Fc receptor high affinity I; Fc gamma RI
There are currently no customer reviews or questions for Human Anti-CD64 x Anti-EGFR Bispecific Antibody (IgG-IgG) (BSIG-H297). Click the button below to contact us or submit your feedback about this product.